Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Keros Therapeutics ( (KROS) ) has provided an update.
On September 8, 2025, Keros Therapeutics announced the presentation of additional clinical data from its Phase 1 trial of KER-065 at the American Society of Bone and Mineral Research 2025 Annual Meeting. The trial, conducted in healthy male volunteers, showed that KER-065 was generally well-tolerated and demonstrated promising results in increasing bone mineral density, suggesting potential benefits for patients with Duchenne muscular dystrophy and bone disorders. The data indicated that KER-065 could balance osteoblast and osteoclast activity, with improvements in bone biomarkers and sustained increases in bone mineral density observed through Day 141.
The most recent analyst rating on (KROS) stock is a Hold with a $18.00 price target. To see the full list of analyst forecasts on Keros Therapeutics stock, see the KROS Stock Forecast page.
Spark’s Take on KROS Stock
According to Spark, TipRanks’ AI Analyst, KROS is a Neutral.
Keros Therapeutics’ overall score reflects strong financial performance and positive corporate events, offset by valuation concerns and technical indicators suggesting potential overbought conditions. The strategic realignment and workforce reduction add uncertainty, impacting the overall score.
To see Spark’s full report on KROS stock, click here.
More about Keros Therapeutics
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat disorders linked to dysfunctional signaling of the TGF-ß family of proteins. The company is a leader in understanding the role of these proteins in the growth, repair, and maintenance of various tissues, including blood, bone, skeletal muscle, adipose, and heart tissue. Keros’ lead product candidate, KER-065, is being developed for neuromuscular diseases, particularly Duchenne muscular dystrophy (DMD).
Average Trading Volume: 512,778
Technical Sentiment Signal: Hold
Current Market Cap: $633.2M
For detailed information about KROS stock, go to TipRanks’ Stock Analysis page.